Dr. Jarbas Barbosa, deputy director of the Pan American Health Organization (PAHO), recognized Cuba´s efforts and results in developing these vaccine candidates.
On Thursday, the first official technical meeting between Cuban, PAHO and the World Health Organization (WHO) specialists was held virtually as part of the international recognition of Cuba’s vaccine candidates.
During the meeting, chaired by Dr. Mariangela Simao, WHO deputy director general for access to medicines, vaccines and pharmaceuticals, the coming steps were tackled to give continuity to this process.
Cuban scientists detailed about results in clinical trials of Soberana 02, Soberana Plus and Abdala candidates, as well as Soberana 01 and Mambisa.
All parties described the meeting as excellent and fruitful, the Business Group of the Biotechnology and Pharmaceutical Industries (BioCubaFarma) posted on Twitter.
On the other hand, the UN Educational, Scientific and Cultural Organization (UNESCO) recognized Cuba’s leadership in producing vaccine candidates against the disease in our region.
The report ‘Covid-19 and vaccination in Latin America and the Caribbean: challenges, needs and opportunities’ detailed that in August 2020 Cuba became the first in this area to receive authorization for clinical trials of Soberana 01, Mambisa, Abdala, Soberana 02 and Soberana Plus candidates.
UNESCO referred to Cuba’s biotechnology industry, made up of over 30 research institutes and BioCubaFarma´s manufacturing companies, in addition to 2,438 patents registered abroad.
pgh/Pll/npg / rbp